Clinical implications of the results of recent atherothrombotic trials on patient management
Department of Cardiology Hemodynamic Unit, Hospital Clínic Barcelona, Villarroel 170, 08036 Barcelona, Spain
* Corresponding author. Tel: +34 93 227 5751, fax: +34 93 451 4148. E-mail address: abetriu{at}clinic.ub.es
Significant advances have been made over the last several years in the treatment of patients with acute coronary syndromes including the introduction and approval of new antithrombin and antiplatelet agents. Results from a number of studies have impacted treatment strategies of patients with and without percutaneous coronary intervention. The study design and results of five trials: OASIS-5 PCI, PCI-ACUITY, TRITON–TIMI-38, FINESSE, and CARESS-in-AMI will be reviewed, and implications for clinical practice presented.
Key Words: Acute coronary syndrome Percutaneous coronary intervention Atherothrombotic trials Glycoprotein IIb/IIIa inhibitors Heparin Clopidogrel